Experience

Davis Polk advised CureVac N.V. on its $245.3 million initial public offering of 15,333,332 of its common shares, which includes 1,999,999 common shares from the full exercise of the…

Davis Polk advised the underwriters on the registered offering of $700 million aggregate principal amount of 1.100% notes due 2030 and $300 million aggregate principal amount of 2.000%…

Davis Polk advised Hangzhou Tigermed Consulting Co., Ltd. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in…

Davis Polk is advising UBS AG London Branch as sponsor in connection with the unification of Unilever’s dual-headed group legal structure under a single parent company, Unilever PLC, to be…

Davis Polk advised the representatives of the underwriters in connection with the $511.5 million SEC-registered offering of 5,500,000 American Depositary Shares of BioNTech SE. In addition,…

Davis Polk advised the joint book-running managers on an offering by Wyndham Destinations, Inc. of $650 million aggregate principal amount of its 6.625% senior secured notes due…

Davis Polk advised the sales agent in connection with an SEC-registered at-the-market offering by InflaRx N.V. of its shares of common stock for up to an aggregate amount of $50…

Davis Polk advised the representatives of the underwriters in connection with an initial public offering of Inventiva S.A.’s 7,478,261 American Depositary Shares. Aggregate gross…

Davis Polk advised Centogene N.V. on its $49 million follow-on public offering of 3,500,000 of its common shares, consisting of 2,000,000 common shares offered by Centogene and 1,500,000…

Davis Polk advised the joint lead managers in connection with the Rule 144A/Regulation S offering by the Hashemite Kingdom of Jordan of $500 million aggregate principal amount of its 4.950%…